BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


SEARCH JOBS

View Clinical Trials from BioPharm Insight


Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.


 Key Statistics


Email:
Ownership:

Web Site: Alexion Pharmaceuticals Inc.
Employees: 1,500
Symbol: ALXN
 



Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Alexion Pharmaceuticals Inc. (ALXN) Release: Researchers To Present New Data On Asfotase Alfa In Pediatric Patients With Hypophosphatasia At The American Society For Bone And Mineral Research 2014 Annual Meeting 8/14/2014 8:07:24 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: European Commission Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 8/1/2014 10:21:58 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: European Medicines Agency Accepts Marketing Authorization Application For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 7/24/2014 11:41:16 AM
Alexion Pharmaceuticals Inc. (ALXN) Reports Second Quarter 2014 Results 7/24/2014 11:18:27 AM
Alexion Pharmaceuticals Inc. (ALXN) Announces The Appointments Of David R. Brennan, M. Michele Burns And Christopher J. Coughlin To Its Board Of Directors 7/16/2014 9:03:36 AM
Alexion Pharmaceuticals Inc. (ALXN) To Report Second Quarter 2014 Results On Thursday, July 24, 2014 7/10/2014 11:24:53 AM
Alexion Pharmaceuticals Inc. (ALXN) And Cincinnati Children's Hospital Medical Center's Launch Rare Disease Innovation Fund 6/23/2014 6:57:46 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: FDA Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 6/17/2014 11:22:27 AM
Alexion Pharmaceuticals Inc. (ALXN) To Present At Investor Conferences 6/3/2014 9:19:02 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: New Data Presented At The ERA-EDTA Congress Demonstrate Efficacy Of Soliris® (Eculizumab) In Broad Range Of Patients With Atypical Hemolytic Uremic Syndrome (Ahus) 6/2/2014 9:00:16 AM
12345678910...